Oscar Health, Inc. reports results for the quarter ended September 30 - Earnings Summary

By Reuters News
  • Oscar Health, Inc. OSCR.N reported quarterly adjusted earnings of 49 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -53 cents. The mean expectation of twelve analysts for the quarter was for a loss of 21 cents per share. Wall Street expected results to range from -53 cents to 7 cents per share.

  • Revenue rose 72.1% to $5.14 billion from a year ago; analysts expected $4.72 billion.

  • Oscar Health, Inc.'s reported EPS for the quarter was 49 cents​.

  • The company reported quarterly net income of $167.28 million.

  • Oscar Health, Inc. shares had risen by 14.1% this quarter and gained 144.9% so far this year.

FORECAST CHANGES

  • The mean earnings estimate of analysts had risen by about 4.8% in the last three months.​

  • In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy," 7 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the life & health insurance peer group is "buy."

  • Wall Street's median 12-month price target for Oscar Health, Inc. is $34.00, about 3.5% below its last closing price of $35.19

This summary was machine generated from LSEG data November 5 at 02:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING

ESTIMATE

ACTUAL

BEAT, MET, MISSED

Sep. 30 2026

-0.21

0.49

Beat

Jun. 30 2026

0.39

1.10

Beat

Mar. 31 2026

1.18

2.07

Beat

Dec. 31 2025

-0.89

-1.24

Missed

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk